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In mouse intestinal tumors induced by the inhibition of APC, the restoration of APC function causes
complete tumor regression with normal differentiation and return of stem cell function irrespective
of whether tumors also carried mutations in Kras and p53. These findings by Dow et al. validate the
Wnt pathway as an exquisite target for intervention.Effective cancer treatments require tar-
gets that upon inactivation cause tumor
cell death, senescence, or that force cells
to differentiate. The dependence of tu-
mors on such targets, which are usually
instrumental in conferring aberrant sig-
naling, has been coined ‘‘oncogene
addiction,’’ implying that tumor cell
growth will be preferentially impaired
upon inhibition of such targets. Addiction
to the inactivation of tumor suppressor
genes is less well documented as restora-
tion of function is more difficult to assess.
For Myc-driven lymphomas lacking func-
tional p53, restoration of p53 results in tu-
mor cell apoptosis, yet mutations in p53
or other components in the pathway
occur easily (Martins et al., 2006). In com-
parison, in a Kras-driven model of non-
small-cell lung cancer, restoration of p53
had very little effect (Junttila et al., 2010).
In this issue of Cell, Dow et al. (2015)
address the dependence of mouse intes-
tinal cancer on the loss of the tumor sup-
pression by APC.
Different tumor types often show an
idiosyncratic mutation pattern with a
preponderance of mutations in a distinct
gene or pathway, indicative of different
wiring. For instance, pancreatic cancers
almost invariably carry mutations in
K-RAS, whereas small-cell lung cancer
shows loss-of-function of the retinoblas-
toma protein. Similarly, colon carcinomas
predominantly bear inactivatingmutations
in APC (a negative regulator of beta-cate-
nin in the Wnt pathway). One has to as-
sume that these predominant lesions are
a requirement for the development of
that specific tumor.However, thequestion
is whether these tumors also require these
lesions for their maintenance, a critical
issue for designing targeted interventions.1494 Cell 161, June 18, 2015 ª2015 ElsevierThe notion that a range of additional, often
quitediverse, drivermutations are found in
these tumors further complicates matters
as these additional lesions could abrogate
the dependency on the initial defect. The
question of addiction of a progressed
tumor can best be answered by genetic
experiments in which the physiological
level of the supposed critical driver lesion
is restored.
Dow et al. use a conditional and induc-
ible short hairpin RNA (shRNA) approach
to control the level of APC in a small sub-
set of intestinal stem cells in the mouse
(Figure 1). Reducing APC to very low
levels results in tumors along the intestine
including colon. Once tumors are detect-
able by endoscopy, they restore normal
levels of APC by switching off the shRNA.
This results in tumor regression. Tumor
cells undergo differentiation toward the
cell types specified by normal intestinal
differentiation. Remarkably, this also oc-
curs in tumors that, besides expressing
reduced APC levels, lack p53 and bear a
dominant active Kras. This illustrates
that loss of APC remains critical for intes-
tinal tumor maintenance even if potent
additional oncogenic lesions have been
acquired that are known to cause tumor
progression in this system.
This implies that cellular processes un-
leashed by APC loss are appealing tar-
gets for intervention. The observation
made in a small fraction of patients that
beta-catenin mutations are found rather
than loss-of-function lesions in APC sug-
gests that beta-catenin or the complexes
it forms with other transcription regulators
could be suitable targets for drug inter-
vention. Indeed, tankyrase inhibitors,
which impair beta-catenin function in
APC mutant cells by stabilizing Axin2Inc.(Huang et al., 2009), have shown to
impede tumor development in pre-clinical
models (Waaler et al., 2012) and are
currently being tested in clinical trials.
A number of observations made in this
study are noteworthy. First of all, the
authors do not see any non-responding
tumors or eventual relapses in their
model, even if APC is restored in the
mutant Kras, p53 setting. A case in point
is the Myc transcription factor. Myc is
a critical driver in many tumors, and
abrogation of its transcription activat-
ing capacity results invariably in tumor
regression with no sign of escapees (Sou-
cek et al., 2008, 2013). In the case of APC,
this lack of escape might be due to the
fact that APC constitutes a critical node
of the Wnt and other signaling pathways
and escape by mutations in APC would
require almost complete suppression of
its activity, at least in this tumor type. In
the study by Dow et al., the required
loss-of-function of both alleles might be
unlikely to occur in view of the relatively
modest tumor mass inherent to mouse
models. In the same vein, activation of
beta-catenin requires specific mutations,
also making the probability low and given
its downstream position in the signaling
pathway alternative lesions might not be
at hand. It would be of interest to see if
one can force escapees in this system,
for instance, by mutagenesis, and what
their nature would be. Furthermore, the
fact that APC controls the degradation of
multiple factors regulating cell prolifera-
tion might add to the strong selection for
APC deletions and therefore its critical
role in colorectal cancer. The Hippo
pathway, another signaling cascade
highly relevant in cancer (Harvey et al.,
2013), is also controlled by the APC
Figure 1. Addressing theRole of
APC in Intestinal Tumor Main-
tenance
(A) Genetic inactivation of Apc in the
mouse intestine, either by LOH in
ApcMin/+ mice (left) or by temporary
Cre expression in intestinal stem
cells in conditionalApcF/Fmice (right)
results in tumors primarily in the
small intestine.
(B) APC suppression by conditional
and doxycyclin inducible expression
of shRNA’s reducing APC in intesti-
nal stem cells results in tumorigen-
esis in small intestine and colon.
Upon doxycylin withdrawal APC re-
turns to physiological levels resulting
in sustained tumor regression. Crypt
homeostasis is restored by inducing
massive differentiation of tumor cells
some of which contribute to the
normal stem cell compartment even
if tumors have acquired additional
oncogenic driver mutations such as
loss of p53 and/or activated K-ras.destruction complex and con-
tributes to the oncogenic ca-
pacity of APC loss (Azzolin
et al., 2014).
Second, the study shows
that the extent of APC reduc-
tion is a critical factor. Only
the most active shRNAs elicit
tumor development. Still, the
tumor latency is significantly
longer than observed for ge-
netic deletion ofApc. This indi-
cates that even very low levels
of this tumor suppressor pro-
tein can substantially impair
tumor development. It also
stresses the requirement for
robust shRNA strategies to
prove addiction. The authors
also make another remarkable
observation. Whereas genetic
APC ablation in mice results
in tumors largely in the
small intestine (Boivin et al.,
2003)—an observation often
used to question the utility
of the mouse as a model
for colon carcinomas—the
shRNA-mediated inhibition of
APC also gives rise to many
colon tumors, suggesting that
the level of this tumor suppres-
sor protein matters and might
be a factor in the preponder-
ance of the specific tumor
subtype that arises. Obviously
such subtleties can also be
brought about by specific mu-
tations in APC, and it will be
worthwhile to more closely
assess the effects of individual
mutations in this regard.
Third, the change brought
about by restoring normal
APC levels in the tumors, even
those carrying the Kras and
p53 lesions, is remarkable.
Cells would stop proliferation
and resume their differentia-
tion program, expressing the
markers normally found in the
intestine. Even more surpris-
ing, the tumor cells that are
marked by fluorescent protein
appear capable of resuming
normal crypt stemcell function,
giving rise over time to fully
fluorescent reporter-labeledCell 161, June 18,normal crypts. Relatively few
normal reporter-labeled crypts
are found upon regression.
Possibly this relates to a rela-
tively small fraction of tumor
cells that are capable of
resuming a normal stem cell
role or to the limited access to
the micro-environmental sig-
nals required for such a role.
Therefore, it would be of inter-
est to follow the remodeling in
these tumors toward normal
functionality over time with a
number of markers that define
the different cell types in the
colon and that read out MAPK
pathway activation.
Altogether, this study ele-
gantly shows the power of
mouse models to give insight
into the role of tumor-causing
lesions, their role in tumor
maintenance, their depen-
dence, or lack thereof, on
other co-occurring mutations,
and the consequences of
restoring normal function.
REFERENCES
Azzolin, L., Panciera, T., Soligo, S.,
Enzo, E., Bicciato, S., Dupont, S.,
Bresolin, S., Frasson, C., Basso, G.,
Guzzardo, V., et al. (2014). Cell 158,
157–170.
Boivin, G.P., Washington, K., Yang,
K.,Ward, J.M., Pretlow, T.P., Russell,2015 ª2015 Elsevier Inc. 1495
R., Besselsen, D.G., Godfrey, V.L., Doetschman,
T., Dove, W.F., et al. (2003). Gastroenterology
124, 762–777.
Dow, L.E., O’Rourke, K.P., Simon, J., Tschaharga-
neh, D.F., van Es, J.H., Clevers, H., and Lowe, S.W.
(2015). Cell 161, this issue, 1539–1552.
Harvey, K.F., Zhang, X., and Thomas, D.M. (2013).
Nat. Rev. Cancer 13, 246–257.
Huang, S.M., Mishina, Y.M., Liu, S., Cheung, A.,
Stegmeier, F., Michaud, G.A., Charlat, O., Wiel-1496 Cell 161, June 18, 2015 ª2015 Elsevierlette, E., Zhang, Y., Wiessner, S., et al. (2009). Na-
ture 461, 614–620.
Junttila, M.R., Karnezis, A.N., Garcia, D., Madriles,
F., Kortlever, R.M., Rostker, F., Brown Swigart, L.,
Pham, D.M., Seo, Y., Evan, G.I., and Martins, C.P.
(2010). Nature 468, 567–571.
Martins, C.P., Brown-Swigart, L., and Evan, G.I.
(2006). Cell 127, 1323–1334.
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J.,
Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart,Inc.L.B., Nasi, S., and Evan, G.I. (2008). Nature 455,
679–683.
Soucek, L., Whitfield, J.R., Sodir, N.M., Masso´-
Valle´s, D., Serrano, E., Karnezis, A.N., Swigart,
L.B., and Evan, G.I. (2013). Genes Dev. 27,
504–513.
Waaler, J., Machon, O., Tumova, L., Dinh, H., Kor-
inek, V., Wilson, S.R., Paulsen, J.E., Pedersen,
N.M., Eide, T.J., Machonova, O., et al. (2012).
Cancer Res. 72, 2822–2832.A Shortcut to Activity-Dependent TranscriptionNikhil Sharma,1 Harrison W. Gabel,1 and Michael E. Greenberg1,*
1Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA
*Correspondence: meg@hms.harvard.edu
http://dx.doi.org/10.1016/j.cell.2015.06.009
Neuronal activity results in the rapid induction of gene transcription through a series of definedmo-
lecular events. Madabhushi et al. describe an unexpected role for the cutting of promoter DNA by
topoisomerase IIB to facilitate transcription of activity-induced genes.Sensory experience induces activity-
dependent gene expression in neurons,
and this process has been implicated in
the function and dysfunction of the ner-
vous system (West and Greenberg,
2011). The ability of a neuron to rapidly
induce gene transcription in response to
sensory stimuli requires the binding of
pre-existing transcription factors such as
CREB, SRF, and MEF2 to promoters and
enhancers. In response to external stim-
uli, these factors become modified, typi-
cally by phosphorylation or dephosphory-
lation, leading to enhancer and promoter
engagement. This is followed by the
release of paused, promoter-bound RNA
polymerase II (RNAPII) complexes result-
ing in productive transcriptional elonga-
tion (Figure 1A). Prior to neuronal activity,
a time when activity-dependent genes are
expressed at low levels, these genes ex-
press hallmarks of highly expressed
genes (e.g., binding by transcription fac-
tors and polymerase, and trimethylation
of Histone H3 at lysine 4 at promoters).
This suggests that activity-dependent
genes are poised for activation but that a
switch or set of switches must be flipped
in order for transcriptional activation to
occur.In this issue of Cell, Madabhushi et al.
(2015) propose that some activity-regu-
lated genes are maintained in a state of
high torsional stress prior to stimulation
such that supercoiling of the DNA keeps
RNAPII from extending into gene bodies.
The authors provide evidence that upon
neuronal depolarization, activation of
Topoisomerase IIB (Topo IIB) leads to
DNA double-stranded breaks (DSBs)
within the promoters, thus allowing the
DNA tounwindandRNAPII toproductively
elongate through gene bodies (Figure 1B).
DSBs have classically been viewed as
unwanted DNA damage and have been
linked to pathological states including
neurological disorders (Madabhushi
et al., 2014). However, recent reports
have noted that neuronal stimulation
leads to the appearance of hallmarks of
DSBs in the nucleus of neurons (Suber-
bielle et al., 2013), including the phos-
phorylation of serine 139 on the histone
variant H2AX (gH2AX), a chromatin mark
deposited on adjacent histones by the
DNA-damage response pathway immedi-
ately after DSBs are detected. This sug-
gested that DSBs might occur as part of
the normal cellular response to neuronal
activation, but where on the genomethese DSBs occur, and what function
they play, has remained unclear.
Madabhushi et al. sought to understand
the effects of DSBs by inducing them in
neurons using a topoisomerase inhibitor
drug, etoposide, and investigating the
effects on gene expression by RNA-
sequencing (RNA-seq) analysis. Etopo-
side traps type II topoisomerase enzymes
(those that make double-stranded cuts in
the DNA) in a state where they remain
bound to cleaved DNA, and this subse-
quently can lead to the formation of
DSBs. Upon etoposide treatment, the au-
thors observe an increase in transcription
at several genes, including Fos, FosB, and
Npas4, all of which are known to be
rapidly transcribed in response to
neuronal activity. Inhibition of the most
prevalent type II topoisomerase in neu-
rons (TopIIB) by RNAi knockdown
conversely leads to blunted induction of
these genes, suggesting that the cutting
of DNA by TopIIB is essential for full
gene activation.
To further explore if activity-dependent
gene induction is linked to DSB formation,
the authors examine the distribution
of gH2AX in activated neurons by
chromatin immunoprecipitation followed
